Is CJC-1295 with ipamorelin and GHRP-2 legal in the United Kingdom?

Three growth hormone secretagogues in one vial, commonly 2 mg each in a 6 mg vial. Two of the three act at exactly the same receptor, which is the fact this product is built to obscure. The combination has never been studied, and adding a second ghrelin-receptor agonist to the first adds the older agent's appetite and cortisol profile without adding a second mechanism.

Three is the number that should stop a buyer. Ipamorelin and GHRP-2 are both agonists at the growth hormone secretagogue receptor, the ghrelin receptor.

Mechanism: Two of the three components are agonists at the same growth hormone secretagogue receptor and are additive at that receptor rather than complementary. The third is a GHRH receptor agonist raising pulse amplitude.

Regulatory history: Not approved. None of the three components is an approved medicine in the United States and no regulator has evaluated any combination of them.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for CJC-1295 with ipamorelin and GHRP-2 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.